arrow
S

Sylvie Rusakiewicz

unicancer
H指数:37
被引数:1.0万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

IntegrAlign: a comprehensive tool for multi-immunofluorescence panel integration through image alignment

IntegrAlign:一种通过图像配准实现多免疫荧光面板集成的综合工具

2025-11-010
OA
Multi-modal image analysis for large-scale cancer tissue studies within IMMUcan

IMMUcan框架内的大规模癌组织研究的多模态图像分析

2025-09-090
OAAI
Myeloid cell networks govern re-establishment of original immune landscapes in recurrent ovarian cancer

髓系细胞网络调控复发性卵巢癌中原有免疫景观的重新建立

2025-07-310
OAAI
Multiplexed high-throughput immune cell imaging in patients with high-risk triple negative early breast cancer: Analysis from the International Breast Cancer Study Group (IBCSG) Trial 22-00
2024-03-011
PRE
PD-1-expressing macrophages and CD8 T cells are independent predictors of clinical benefit from PD-1 inhibition in advanced mesothelioma

PD-1-expressing巨噬细胞和CD8 T细胞是晚期间皮瘤PD-1抑制临床获益的独立预测因子

2023-10-253
OAAI
Neoantigen-specific CD8 T cells with high structural avidity preferentially reside in and eliminate tumors

具有高结构亲和力的新抗原特异性CD8 T细胞优先驻留并消除肿瘤

2023-06-0627
OAAI
The immunopeptidome landscape associated with T cell infiltration, inflammation and immune editing in lung cancer

与肺癌中T细胞浸润,炎症和免疫编辑相关的免疫肽组景观

2023-05-0135
OAAI
Pathologic complete response rate across triple negative breast cancer subtypes in the IMMUcan study
2023-04-040
PRE
Low-Dose Radiotherapy Reverses Tumor Immune Desertification and Resistance to Immunotherapy

低剂量放射治疗可逆转肿瘤免疫荒漠化和对免疫疗法的抵抗力

2021-09-03215
OAAI
Cell-autonomous inflammation of BRCA1-deficient ovarian cancers drives both tumor-intrinsic immunoreactivity and immune resistance via STING

BRCA1-deficient卵巢癌的细胞自主炎症通过STING驱动肿瘤固有的免疫反应性和免疫抗性

2021-07-0174
OAAI
A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial
2020-12-01150
OAAI
Development of an optimized closed and semi-automatic protocol for Good Manufacturing Practice manufacturing of tumor-infiltrating lymphocytes in a hospital environment

开发优化的封闭和半自动协议,用于良好的制造规范在医院环境中制造肿瘤浸润淋巴细胞

2020-12-0112
PREAI
18F-FDG PET metabolic-to-morphological volume ratio predicts PD-L1 tumour expression and response to PD-1 blockade in non-small-cell lung cancer

18F-FDG PET代谢与形态体积比预测非小细胞肺癌PD-L1肿瘤表达和对PD-1阻断的反应

2019-06-1865
PREAI
T-cell bispecific antibodies in node-positive breast cancer: novel therapeutic avenue for MHC class I loss variants
2019-06-0123
OAAI